KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Deferred Tax Liability (2018 - 2025)

Historic Non-Current Deferred Tax Liability for Emergent BioSolutions (EBS) over the last 10 years, with Q3 2025 value amounting to $36.3 million.

  • Emergent BioSolutions' Non-Current Deferred Tax Liability fell 1336.52% to $36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.3 million, marking a year-over-year decrease of 1336.52%. This contributed to the annual value of $41.7 million for FY2024, which is 2920.2% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Non-Current Deferred Tax Liability stood at $36.3 million, which was down 1336.52% from $46.5 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Non-Current Deferred Tax Liability registered a high of $130.7 million during Q4 2021, and its lowest value of $34.8 million during Q1 2024.
  • Moreover, its 5-year median value for Non-Current Deferred Tax Liability was $53.3 million (2021), whereas its average is $65.4 million.
  • In the last 5 years, Emergent BioSolutions' Non-Current Deferred Tax Liability soared by 11490.57% in 2022 and then crashed by 5399.47% in 2023.
  • Emergent BioSolutions' Non-Current Deferred Tax Liability (Quarter) stood at $130.7 million in 2021, then fell by 4.06% to $125.4 million in 2022, then plummeted by 53.03% to $58.9 million in 2023, then dropped by 29.2% to $41.7 million in 2024, then fell by 12.95% to $36.3 million in 2025.
  • Its Non-Current Deferred Tax Liability stands at $36.3 million for Q3 2025, versus $46.5 million for Q2 2025 and $60.4 million for Q1 2025.